Global Genitourinary Partnering 2012-2018: Deal trends, players and financials
|発行||Current Partnering, a division of Wildwood Ventures Limited||商品コード||250303|
|出版日||ページ情報||英文 500+ Pages
|泌尿生殖器関連の各種提携契約：契約条件・合意内容 Global Genitourinary Partnering 2012-2018: Deal trends, players and financials|
|出版日: 2018年02月01日||ページ情報: 英文 500+ Pages||
The‘ Global Genitourinary Partnering 2012 to 2018: Deal trends, players and financials report ’provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies.
‘Global Genitourinary Partnering 2012 to 2018’ provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.
The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Genitourinary deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Genitourinary deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2012. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.
‘Global Genitourinary Partnering 2012 to 2018 ’is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.
‘Global Genitourinary Partnering 2012 to 2018’ includes:
The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie's disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.
In Global Genitourinary Partnering 2012 to 2018, available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The ‘Global Genitourinary Partnering 2012 to 2018’ report provides comprehensive access to available deals and contract documents for over 3500 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:
‘Global Genitourinary Partnering 2012 to 2018 ’provides the reader with the following key benefits: